Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Current Assets (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Current Assets for 16 consecutive years, with $20.7 million as the latest value for Q1 2026.

  • Quarterly Current Assets rose 22.01% to $20.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $20.7 million through Jan 2026, up 22.01% year-over-year, with the annual reading at $22.4 million for FY2025, 55.64% down from the prior year.
  • Current Assets for Q1 2026 was $20.7 million at PharmaCyte Biotech, down from $23.0 million in the prior quarter.
  • The five-year high for Current Assets was $86.8 million in Q1 2022, with the low at $17.0 million in Q1 2025.
  • Average Current Assets over 5 years is $52.3 million, with a median of $61.5 million recorded in 2024.
  • The sharpest move saw Current Assets skyrocketed 5353.31% in 2022, then plummeted 72.42% in 2025.
  • Over 5 years, Current Assets stood at $77.2 million in 2022, then dropped by 4.49% to $73.7 million in 2023, then plummeted by 71.07% to $21.3 million in 2024, then rose by 7.92% to $23.0 million in 2025, then fell by 10.1% to $20.7 million in 2026.
  • According to Business Quant data, Current Assets over the past three periods came in at $20.7 million, $23.0 million, and $19.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.